Kinase Inhibitor News and Research

RSS

A protein kinase inhibitor is a type of enzyme inhibitor that specifically blocks the action of one or more protein kinases.

New compound, AMN107, 20 times more potent than Gleevec for chronic myelogenous leukemia treatment

A laboratory study led by researchers at Dana-Farber Cancer Institute has shown that a potent and highly selective therapy for chronic myelogenous leukemia (CML) may ultimately be more effective than Gleevec®, the current standard of care.

21 Feb 2005

New compound AMN107 may help treat some imatinib resistant cancer cases

As scientists uncover the precise molecular mechanisms that underlie effective cancer treatments, they gain invaluable insight into why predominantly successful treatments fail for some patients.

14 Feb 2005

Potential new therapies for cancer and bleeding disorders

Lexicon Genetics announced today that it has advanced two of its drug discovery programs into preclinical development in preparation for investigational new drug (IND) applications.

10 Jan 2005

Scientists have determined the crystal structure of a protein kinase C (PKC) isozyme

This structure should prove extremely useful in the rational design of small molecule inhibitors of PKCÈ, which has been implicated in T-cell mediated disease processes including inflammation and autoimmunity.

19 Nov 2004

Micro-array technology is revolutionising current drug development

Gene expression micro-array technology is benefiting all phases of the discovery, development and subsequent use of new cancer therapeutics

29 Oct 2004

Potential new treatment strategy against metastatic cancer cells

A team of scientists at The Scripps Research Institute has identified a potential treatment strategy against metastatic cancer cells that has never been tried before.

25 Oct 2004

Scientists have developed a new technology capable of improving survival outcomes after bone marrow transplantation

The study was published in the September issue of the prestigious medical journal, British Journal of Hematology. The technology involves the rational design and application of tyrosine kinase inhibitors for the treatment of leukemia, lymphoma, and graft versus host disease.

8 Oct 2004

FDA fast tracks temsirolimus, first-line treatment of poor-prognosis patients with advanced renal cell carcinoma

Wyeth Pharmaceuticals has announced that the U.S. Food and Drug Administration has granted a new "fast track" designation for temsirolimus (CCI-779), an investigational mTOR kinase inhibitor, in the first-line treatment of poor-prognosis patients with advanced renal cell carcinoma (RCC).

18 Aug 2004

Identification of PIK3CA as an oncogene associated with brain cancers opens the door to new screening processes

Hotspots in two areas of a gene that encodes a specific signaling enzyme, or kinase, are vulnerable to a variety of mutations found in five types of brain cancers, according to a report published in the August 1 issue of the journal Cancer Research.

2 Aug 2004

New compound that is designed to overcome Gleevec resistance

One of the truly spectacular success stories in modern oncology is the development and implementation of Gleevec, a drug that virtually halts the progress of chronic myeloid leukemia. Yet for some patients who harbor particularly stubborn genetic mutations, Gleevec fails miserably.

17 Jul 2004

New compound, ZK-CDK combines the inhibition of tumour cell growth as well as inhibition of tumour angiogenesis in one single molecule

Treatment with a new dual cell cycle and angiogenesis pathway inhibitor blocks VEGF-induced vascular permeability, inhibits tumour angiogenesis and induces apoptosis in human tumour models

7 Jul 2004

Exelixis files new drug application for a proprietary novel anticancer compound

Exelixis, Inc. has submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) for XL999, a proprietary novel anticancer compound.

29 Jun 2004

Cancer drug gefitinib (Iressa) may be able to restore tamoxifen's anticancer activity

A new study has found a possible mechanism for tamoxifen resistance in breast cancer and provides evidence that another cancer drug--gefitinib (Iressa)--may be able to restore tamoxifen's anticancer activity.

15 Jun 2004

Oxygen delivered through the nose may improve poor vision caused by diabetic macular edema

Oxygen delivered through the nose may improve poor vision caused by diabetic macular edema, fluid buildup in the part of the eye responsible for central vision, according to a pilot study by scientists at Johns Hopkins and the National Eye Institute.

18 May 2004

Developing smart drugs

Dana-Farber Cancer Institute Researchers, sensing an opening in the cancer battle, are mounting a quick thrust to flush out suspected molecular cancer triggers in tumor cells.

30 Apr 2004

Breast feeding increases choline which means more brain cells

Five years ago, University of North Carolina at Chapel Hill researchers first reported finding that the nutrient choline played a critical role in memory and brain function by positively affecting the brain’s physical development. Differences in development influenced action, the scientists and their colleagues found. In animal experiments conducted at Duke University, both young and old rats performed significantly better on memory tasks if they received enough choline before birth compared with same-age rats whose mothers were fed choline-deficient diets. The latter showed deficits in the hippocampus and septums of their brains.

22 Mar 2004

New treatment for heart attacks

A team led by scientists at The Scripps Research Institute has developed a potential new treatment for heart attacks. The therapy inhibits fluid leakage from cardiac blood vessels following a heart attack and thereby significantly prevents long-term heart damage and improves survival.